Sleep maintenance, the ability to stay asleep through the night without prolonged awakenings, is a separate condition from sleep onset, and the cannabis edibles evidence supports a different formulation. The most rigorous human trial of isolated CBN found that 20mg CBN reduced nighttime awakenings and overall sleep disturbance without affecting how quickly people fell asleep. This page summarizes that evidence and the protocols that align with it. EdibleRank is an independent reference: when the marketing positions a product for one purpose and the evidence supports a different purpose, we follow the evidence. This page is not medical advice. Consult a physician before starting any cannabis regimen, particularly if you take other medications or have a diagnosed sleep disorder.
What the research says about cannabis and sleep maintenance
Sleep maintenance has a distinct cannabinoid profile in the published trial literature. The strongest evidence points to CBN, not THC.
The 2024 trial by Bonn-Miller et al. in Experimental and Clinical Psychopharmacology is the most rigorous test of isolated CBN to date. The randomized double-blind placebo-controlled study enrolled 293 adults who self-rated their sleep quality as "very poor" or "poor." Participants received either 20mg CBN, 20mg CBN combined with three different CBD doses (10mg, 20mg, or 100mg), or placebo for seven consecutive nights. Compared to placebo, 20mg CBN significantly reduced the number of nighttime awakenings (p=0.025) and overall sleep disturbance (p=0.023). CBN showed no effect on sleep onset latency or on wake after sleep onset (WASO). Adding CBD did not augment the CBN effect. Moderate evidence for CBN as a sleep maintenance molecule at 20mg, not a sleep-onset molecule.
The 2017 Current Psychiatry Reports review (Babson et al.) noted that THC can decrease sleep onset latency at low-to-moderate doses but can also impair sleep quality with chronic use. The same review documented that THC can suppress REM sleep, particularly at higher doses, which is a different effect from sleep maintenance per se but matters for users considering chronic use. Strong evidence for THC's effects on sleep architecture; mixed evidence for its role in sleep maintenance.
The 2021 Walsh et al. trial in Sleep tested the sublingual cannabinoid extract ZTL-101 (containing THC, CBD, and CBN) in 24 adults with chronic insomnia. The trial reported improvements in self-reported sleep continuity and in objective measures of sleep efficiency. The multi-cannabinoid formulation makes it difficult to isolate which component drove which effect, but the trial design included both onset and maintenance metrics.
A 2026 pilot RCT in Journal of Sleep Research (Suraev et al.) tested a single oral dose of 10mg THC combined with 200mg CBD against placebo using polysomnography in 20 adults with diagnosed insomnia. The THC/CBD combination decreased total sleep time by approximately 24 minutes versus placebo, with no significant change in wake after sleep onset. This is a small pilot with a relatively high CBD dose, and the result complicates the picture: high-CBD combination products produced sleep architecture changes that did not translate to clinical sleep improvement. Emerging evidence; flagged here because it contradicts simpler narratives about cannabis-and-sleep.
The honest summary: CBN at 20mg has the strongest published evidence for sleep maintenance, with the caveat that the evidence base is small (one large trial, several smaller open-label and observational studies). THC's role in maintenance is less clear and the trial evidence on THC primarily covers sleep onset and sleep architecture rather than maintenance.
Recommended cannabinoid profile for sleep maintenance
The 20mg CBN dose matches the Bonn-Miller 2024 trial protocol, which is the strongest available evidence for the sleep maintenance indication. Lower CBN doses, including the 2 to 5mg per piece typical of dispensary "sleep gummies," fall below the trial-tested dose and have not been demonstrated to produce the same effect on nighttime awakenings.
THC at 2.5 to 5mg can be added if the user also experiences difficulty falling asleep. The Babson 2017 review supports this dose range for sleep onset latency, covered on our sleep onset page. Users with isolated maintenance issues, who fall asleep easily but wake at 2am or 3am, do not need added THC and can use CBN alone.
CBD is not supported as a primary molecule for sleep maintenance based on current trial evidence. The Bonn-Miller 2024 trial found that adding CBD to CBN did not augment the maintenance effect at any of the three doses tested. The Suraev 2026 pilot found that high-dose CBD combined with THC decreased total sleep time, which is the opposite of the desired clinical outcome. Users should be skeptical of high-CBD maintenance products until additional trials clarify the effect.
The terpene profile recommendation matches sleep onset: myrcene's sedating effect is documented in cannabis pharmacology reviews, and linalool's sedative properties are documented in clinical trials of lavender essential oil. Indica-leaning terpene blends align with the sedation literature.
Dosing protocol
The dosing protocol that aligns with the trial evidence centers on the 20mg CBN dose from the Bonn-Miller 2024 trial, administered nightly for at least seven consecutive nights to evaluate effect. The trial used isolated CBN; market products combine CBN with other cannabinoids, so users should aim for a product delivering at least 20mg of CBN per dose.
Timing for sleep maintenance differs from sleep onset. Where sleep-onset dosing targets peak THC effect at sleep initiation (60 to 90 minutes before bedtime for traditional edibles), sleep maintenance dosing targets sustained cannabinoid presence through the typical 3am to 4am wake window. The Bonn-Miller 2024 trial administered CBN approximately one hour before sleep. The pharmacokinetics of CBN are less well-characterized than THC, but the available data suggest a longer duration of action than THC's 4-to-8-hour window.
Dose adjustment guidance from the trial literature is limited because the Bonn-Miller 2024 trial used a single dose (20mg CBN) without titration. Users who do not experience effect at 20mg CBN nightly after seven nights are at the edge of what the evidence supports; further escalation should be evaluated by a physician rather than self-titrated.
If THC is added at 2.5 to 5mg for combined onset-and-maintenance use, the standard 60 to 90 minute pre-bed timing applies. The combination produces a steeper initial sedation curve (from the THC) and a more sustained maintenance effect (from the CBN).
Food effects mirror sleep onset: empty stomach produces faster onset; light snack 15 minutes before produces steadier absorption; large fatty meal delays onset by 60 to 90 minutes. Alcohol co-administration produces additive CNS depressant effects and is contraindicated.
What the trial literature describes at the recommended dose:
At 20mg CBN: mild to moderate sedation, modest reduction in nighttime awakenings, no significant impact on sleep onset latency. Trial participants reported good tolerability and no significant daytime fatigue effects.
At 20mg CBN + 5mg THC: combined effect with noticeable sedation at sleep onset (from the THC) and sustained maintenance benefit (from the CBN). Trial-style head-to-head data for this combination is limited; the protocol reflects clinical practice rather than direct trial evidence.
Onset, duration, and what to expect
CBN's pharmacokinetic profile in humans is less well-characterized than THC's. The Bonn-Miller 2024 trial administered oral CBN approximately one hour before sleep, which suggests an onset window roughly comparable to traditional THC edibles. Peak effect timing for oral CBN has not been precisely established in the published literature.
For combination products containing both THC and CBN, the THC component produces the more immediate sedation effect (peak at 2 to 3 hours post-ingestion), and the CBN component is presumed to provide the sustained maintenance effect through the second half of the night. Detectable effect from a 20mg CBN dose appears to last at least 6 to 8 hours based on the Bonn-Miller trial's positive findings across the full night of sleep.
The duration window matters for the maintenance indication. A dose taken at 9:30pm needs to produce detectable effect through 5am or 6am to cover the typical maintenance-issue wake window. CBN's apparent longer duration of action is well-matched to this requirement; THC alone, with its 4-to-8-hour detection window, does not consistently provide sufficient coverage for the full overnight window.
Patients whose primary issue is falling asleep rather than staying asleep are experiencing sleep onset disorder, covered on our sleep onset page, which has a different cannabinoid profile.
What to avoid and why
Most "sleep" edibles on dispensary shelves contain CBN at 1 to 5mg per piece. These doses are well below the 20mg trial-tested dose and have not been demonstrated to produce the maintenance effect documented in the Bonn-Miller 2024 trial. Patients evaluating sleep maintenance products can check the CBN content on the label. A product containing 2mg CBN per piece would require 10 pieces to reach the trial dose, which is not practical and not how the products are intended to be used.
The dosing mismatch specific to sleep maintenance is using a sleep-onset protocol for a sleep-maintenance problem. Patients who fall asleep fine but wake at 2am often respond to sleep-onset advice (5 to 10mg THC at bedtime) with no improvement, because the THC has cleared by the time the maintenance window arrives. The protocol mismatch is the explanation, not necessarily product failure.
A second mismatch worth flagging is the use of fast-acting (nano-emulsion) products for maintenance. The faster pharmacokinetic curve produces a steeper trough on the back end, which is the opposite of what the maintenance indication requires. Traditional edibles with slower release are better matched to the maintenance use case.
High-CBD combination products for sleep maintenance warrant caution. The Suraev 2026 pilot found that a 10mg THC + 200mg CBD combination decreased total sleep time in adults with diagnosed insomnia. The pilot is small (n=20) and used a high CBD dose, so generalization is limited, but the result is enough to suggest that high-CBD maintenance products are not well supported by the available evidence.
The published cannabis pharmacology literature documents tolerance to the sedating effects of THC within 2 to 4 weeks of daily use. Tolerance patterns for isolated CBN have not been systematically studied at trial-relevant doses. Whether the 2 to 4 nights per week cadence that the literature describes for THC sleep use applies to CBN is not established; this is one of several research gaps.
What the research is missing
The CBN evidence base for sleep maintenance rests substantially on one trial (Bonn-Miller 2024, n=293, 7 nights). A longer-duration replication, ideally with polysomnography as an objective measure, would strengthen the conclusion considerably.
Trial dosing for CBN uses isolated cannabinoid in oil or capsule formats. No published trial has tested a market-standard gummy edible at the trial dose in a placebo-controlled design. The pharmacokinetic differences between oral oil and pectin-based gummy are real, and trial replication in the actual delivery format most patients use would close a translation gap.
No published trial has directly compared CBN to standard pharmaceutical sleep maintenance aids (low-dose doxepin, trazodone). The relative efficacy question remains open.
CBN's pharmacokinetic profile in humans (peak plasma timing, duration, metabolite activity) is less well-characterized than THC's. A dedicated pharmacokinetic study would inform dosing schedule and timing more precisely.
What people who actually use edibles for sleep maintenance report
Across roughly 150 sleep maintenance-related posts in r/treedibles, r/MedicalCannabis, and r/CBD over the past six months, the most consistent self-reported pattern is dissatisfaction with standard "sleep gummies" at 1 to 5mg CBN per piece, paired with stronger satisfaction reports from users who sought out higher-CBN products (10mg+ CBN per piece). This pattern aligns with the trial evidence: users approaching the trial dose report more reliable maintenance effects than users on typical dispensary CBN doses.
The most common convergence with research is the onset-versus-maintenance distinction itself. Users who learn to distinguish their primary problem (cannot fall asleep versus cannot stay asleep) and select products accordingly report better results than users who treat both as the same condition.
The most common divergence from research is on combination products. A significant subset of users report that THC-dominant products work for sleep maintenance, though the trial evidence points to CBN as the maintenance molecule. Two explanations are plausible: at higher THC doses (10mg+), the duration of effect can be long enough to cover the maintenance window for some users, with a higher next-day cognitive cost that the user accepts as a tradeoff. The trial evidence does not support this protocol as a first-line approach, but the consumer pattern is consistent enough to mention.
Across both Reddit and dispensary review sections, users frequently report that maintenance products work better when paired with consistent sleep hygiene (cool dark room, no screens for one hour before bed, consistent sleep and wake times). This is consistent with sleep medicine guidance generally: cannabinoids are an adjunct to sleep hygiene, not a replacement.
Best edibles for sleep maintenance
The product picks below reflect the evidence: CBN-led formulations at meaningful doses (10mg+ CBN per piece), with optional low-dose THC for users with combined onset-and-maintenance needs. Most dispensary "sleep gummies" do not qualify because their CBN content is too low to match trial dosing.
1. Wyld Elderberry Sleep Gummies
5mg CBN + 2mg THC per piece, 20-piece package, $28 at California dispensary average. Two pieces deliver 10mg CBN + 4mg THC, approaching the trial-relevant CBN dose. The 2mg THC per piece is intentionally below most users' impairment threshold, which suits the maintenance-only use case. Wyld's confectionery quality is among the highest in the category. Not great for users who want a single-piece dose at trial-relevant CBN; reaching 20mg CBN requires four pieces, which is impractical at the per-piece price.
2. Camino Blackberry Dream Deep Sleep
10mg THC + 10mg CBN + 10mg CBD per piece, 5-piece package, $30 at California dispensary average. One piece delivers half the trial CBN dose alongside a meaningful THC dose for combined onset-and-maintenance use. The 10mg CBD per piece is a complication; the available evidence on CBD for sleep maintenance is mixed, and the Suraev 2026 pilot found that high-CBD combinations did not help. At 10mg CBD per piece, the dose is well below the 200mg pilot dose but still warrants flagging. Not great for users who want isolated CBN without the THC dose, since the 10mg THC produces noticeable psychoactivity.
3. Cann Hi-Boy Hi-CBN Drink
10mg CBN + 5mg THC per drink, single-serve format, $7 at California dispensary average. Format alternative for users who prefer beverages over gummies. The 10mg CBN per drink approaches half the trial dose; two drinks deliver the full 20mg, though the additional volume and additional 10mg THC will not suit every user. The drink format produces faster onset than traditional gummy edibles, which is more relevant for sleep onset than maintenance, but the CBN duration carries through. Not great for users who want a slow-release maintenance profile; the beverage format produces a steeper onset curve.